Proton pump inhibitor prophylaxis after Roux-en-Y gastric bypass: A national survey of surgeon practices

Published:October 10, 2022DOI:


      • Most surgeons (85.4%) administered prophylactic proton pump inhibitors (PPIs) to their Roux-en-Y gastric bypass (RYGB) patients
      • Pantoprazole was the most common type of PPI prophylaxis during hospitalization
      • Omeprazole was the most common type of PPI prophylaxis postdischarge
      • The duration of PPI use varied based on the presence of preoperative reflux



      Proton pump inhibitors (PPIs) are frequently used after Roux-en-Y gastric bypass (RYGB) to prevent marginal ulceration. The optimal duration of PPI treatment after surgery to minimize ulcer development is unclear.


      Assess bariatric surgeon practice variability regarding postoperative PPI prophylaxis.


      Survey of medical directors of Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program–accredited centers.


      Members of the American Society for Metabolic and Bariatric Surgery research committee developed and administered a web-based anonymous survey in November 2021 to bariatric surgeons of Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program–accredited programs detailing questions related to surgeons’ use of PPI after RYGB including patient selection, medication, dosage, and treatment duration.


      The survey was completed by 112 surgeons (response rate: 52.6%). PPIs were prescribed by 85.4% of surgeons for all patients during their hospitalization, 3.9% for selective patients, and 10.7% not at all. After discharge, 90.3% prescribed PPIs. Pantoprazole was most often used during hospitalization (38.5%), while omeprazole was most prescribed (61.7%) after discharge. The duration of postoperative PPI administration varied; it was 3 months in 43.6%, 1 month in 20.2%, and 6 months in 18.6% of patients. Finally, surgeons’ practice setting and case volume were not associated with the duration of prophylactic PPI administration after RYGB.


      PPI administration practices vary widely among surgeons after RYGB, which may be related to the limited comparative evidence and guidelines on best duration of PPI administration. Large prospective clinical trials with objective outcome measures are needed to define optimal practices for PPI prophylaxis after RYGB to maximize clinical benefit.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Estimate of Bariatric Surgery Numbers, 2011-2019. American Society for Metabolic and Bariatric Surgery (ASMBS) [cited 2022 Jun 5].
        (Available from:)
        • Colquitt J.L.
        • Pickett K.
        • Loveman E.
        • Frampton G.K.
        Surgery for weight loss in adults.
        Cochrane Database Syst Rev. 2014; 2014: Cd003641
        • Angrisani L.
        • Santonicola A.
        • Iovino P.
        • Vitiello A.
        • Zundel N.
        • Buchwald H.
        • et al.
        Bariatric surgery and Endoluminal procedures: IFSO Worldwide survey 2014.
        Obes Surg. 2017; 27: 2279-2289
        • Moon R.C.
        • Teixeira A.F.
        • Goldbach M.
        • Jawad M.A.
        Management and treatment outcomes of marginal ulcers after Roux-en-Y gastric bypass at a single high volume bariatric center.
        Surg Obes Relat Dis. 2014; 10: 229-234
        • Gumbs A.A.
        • Duffy A.J.
        • Bell R.L.
        Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass.
        Surg Obes Relat Dis. 2006; 2: 460-463
        • Dallal R.M.
        • Bailey L.A.
        Ulcer disease after gastric bypass surgery.
        Surg Obes Relat Dis. 2006; 2: 455-459
        • Sapala J.A.
        • Wood M.H.
        • Sapala M.A.
        • Flake Jr., T.M.
        Marginal ulcer after gastric bypass: a prospective 3-year study of 173 patients.
        Obes Surg. 1998; 8: 505-516
        • MacLean L.D.
        • Rhode B.M.
        • Nohr C.
        • Katz S.
        • McLean A.P.
        Stomal ulcer after gastric bypass.
        J Am Coll Surg. 1997; 185: 1-7
        • Howard L.
        • Malone M.
        • Michalek A.
        • Carter J.
        • Alger S.
        • Van Woert J.
        Gastric bypass and Vertical Banded Gastroplasty- a prospective randomized comparison and 5-year Follow-up.
        Obes Surg. 1995 Feb; 5: 55-60
        • Coblijn U.K.
        • Goucham A.B.
        • Lagarde S.M.
        • Kuiken S.D.
        • van Wagensveld B.A.
        Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review.
        Obes Surg. 2014; 24: 299-309
        • Rasmussen J.J.
        • Fuller W.
        • Ali M.R.
        Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients.
        Surg Endosc. 2007; 21: 1090-1094
        • Coblijn U.K.
        • Lagarde S.M.
        • de Castro S.M.
        • Kuiken S.D.
        • van Tets W.F.
        • van Wagensveld B.A.
        The influence of prophylactic proton pump inhibitor treatment on the development of symptomatic marginal ulceration in Roux-en-Y gastric bypass patients: a historic cohort study.
        Surg Obes Relat Dis. 2016; 12: 246-252
        • Ying V.W.
        • Kim S.H.
        • Khan K.J.
        • Farrokhyar F.
        • D'Souza J.
        • Gmora S.
        • et al.
        Prophylactic PPI help reduce marginal ulcers after gastric bypass surgery: a systematic review and meta-analysis of cohort studies.
        Surg Endosc. 2015; 29: 1018-1023
        • Steinemann D.C.
        • Bueter M.
        • Schiesser M.
        • Amygdalos I.
        • Clavien P.-A.
        • Nocito A.
        Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey.
        Obes Surg. 2014; 24: 741-746
        • Mechanick J.I.
        • Apovian C.
        • Brethauer S.
        • Garvey W.T.
        • Joffe A.M.
        • Kim J.
        • et al.
        Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.
        Surg Obes Relat Dis. 2020; 16: 175-247
      2. American Society of Metabolic and Bariatric Surgery (ASMBS) Research committee [cited 2022 Jun 5].
        (Available from)
        • Scally B.
        • Emberson J.R.
        • Spata E.
        • Reith C.
        • Davies K.
        • Halls H.
        • et al.
        Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
        Lancet Gastroenterol Hepatol. 2018; 3: 231-241
        • Mo C.
        • Sun G.
        • Wang Y.Z.
        • Lu M.L.
        • Yang Y.S.
        PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal Injury associated with low-dose Aspirin: systematic review and meta-analysis.
        PLoS One. 2015; 10: e0131558
        • Raftopoulos I.
        • Zainabadi K.
        P7: Effect of histamine-2 blockers or proton pump inhibitors on the incidence of anastomotic ulcer after laparoscopic Roux-en-Y gastric bypass.
        Surg Obes Relat Dis. 2007; 3: 301
        • Kang X.
        • Zurita-Macias L.
        • Hong D.
        • Cadeddu M.
        • Anvari M.
        • Gmora S.
        A comparison of 30-day versus 90-day proton pump inhibitor therapy in prevention of marginal ulcers after laparoscopic Roux-en-Y gastric bypass.
        Surg Obes Relat Dis. 2016; 12: 1003-1007
        • Hedberg J.
        • Hedenström H.
        • Nilsson S.
        • Sundbom M.
        • Gustavsson S.
        Role of gastric acid in stomal ulcer after gastric bypass.
        Obes Surg. 2005; 15: 1375-1378
        • Yun G.W.
        • Trumbo C.W.
        Comparative response to a survey executed by post, E-mail, & web form.
        J Com Med Commun. 2000; 6: 0
        • Sheehan K.B.
        E-Mail survey response rates: a review.
        J Com Med Commun. 2001; 6: 0
        • Van Loon A.J.
        • Tijhuis M.
        • Picavet H.S.
        • Surtees P.G.
        • Ormel J.
        Survey non-response in The Netherlands: effects on prevalence estimates and associations.
        Ann Epidemiol. 2003; 13: 105-110